Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Cross-bridge Cycle01:26

Cross-bridge Cycle

As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Healthcare priorities and needs for LGBTQIA+ people with cystic fibrosis: A concept mapping study.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same author

Apolipoprotein L1 Gene Genotype and Kidney Outcomes After Living Kidney Donation.

JAMA internal medicine·2026
Same author

The sociocultural environment and the mental health of sexual and gender minority parents.

Annals of epidemiology·2026
Same author

Associations of employment gain, employment loss and prolonged unemployment with depressive symptoms over time among sexual and gender minority adults in the USA: a retrospective cohort study.

BMJ public health·2026
Same author

Validation of the Brief Assessment of Stress and Eating (BASE) in transgender and gender-diverse adults.

Eating behaviors·2026
Same author

Pathways and Roadblocks: Navigating Family-Building for Sexual and Gender Minority People Assigned Male at Birth.

Perspectives on sexual and reproductive health·2026

Video Experimental Relacionado

Updated: Jul 4, 2026

Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis
06:12

Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis

Published on: January 11, 2014

La atrofia muscular espinal es atrofia muscular espinal.

Mitchell R Lunn1, Ching H Wang

  • 1Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

Lancet (London, England)
|June 24, 2008
PubMed
Resumen

La atrofia muscular espinal (AMS) es una enfermedad genética que causa pérdida de neuronas motoras y debilidad muscular. Los avances en la comprensión de su base molecular han llevado a nuevas estrategias terapéuticas y una mejor atención al paciente.

Más Videos Relacionados

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice
05:55

Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice

Published on: October 3, 2011

Videos de Experimentos Relacionados

Last Updated: Jul 4, 2026

Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis
06:12

Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis

Published on: January 11, 2014

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice
05:55

Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice

Published on: October 3, 2011

Área de la Ciencia:

  • Neurología Neurología.
  • Genética La genética.
  • Biología Molecular Biología Molecular

Sus antecedentes:

  • La atrofia muscular espinal (AMS) es un trastorno neurodegenerativo autosómico recesivo.
  • Se caracteriza por degeneración de las neuronas motoras, atrofia del músculo esquelético y debilidad generalizada.
  • Causada por una alteración homocigótica del gen del Neurón Motor de Supervivencia 1 (SMN1).

Objetivo del estudio:

  • Para proporcionar una revisión exhaustiva de la atrofia muscular espinal.
  • Integrar las manifestaciones clínicas, la patogénesis molecular, las estrategias de diagnóstico y los desarrollos terapéuticos.
  • Discutir la evidencia de los ensayos clínicos y los cambios en el estándar de atención.

Principales métodos:

  • Revisión de la literatura y síntesis de la investigación existente.
  • Análisis de las manifestaciones clínicas y la patogénesis molecular.
  • Evaluación de las estrategias de diagnóstico y desarrollo terapéutico, incluidos los datos de ensayos clínicos.

Principales resultados:

  • Elucidación de los mecanismos de la patogénesis molecular.
  • Desarrollo de estrategias de tratamiento dirigidas a la región del gen SMN1.
  • Identificación de agentes terapéuticos candidatos en varias etapas de desarrollo.

Conclusiones:

  • Los avances en la tecnología médica han alterado significativamente el estándar de atención para los pacientes con AME.
  • La investigación en curso continúa refinando los enfoques de diagnóstico y las intervenciones terapéuticas.
  • Una comprensión completa de la AME es crucial para el manejo eficaz de los pacientes.